Zevra Therapeutics, Inc. ZVRA Fair Value Adjustment Related To Derivative Instrument

Other financials

Revenue$36.2M+77.5%

Gross profit$34.3M+80.1%

Operating income$52.1M+1,073%

Net income$37.9M+1,323%

EPS (diluted)$0.60+1,100%

Cash & equivalents$95.6M+156%

Total debt$1.1M-98.1%

Total equity$205.8M+402%

Total assets$278.6M+61.3%

Operating cash flow$6.1M+175%

CapEx$35.0K-64.6%

Free cash flow$6.1M+173%

Market cap$782.09M+58.2%

Enterprise value$687.64M+32.5%

P/E6.3×—

P/S6.4×-5.8×

Gross margin86.1%+7.2pp

Operating margin-103.9%-43.0pp

Net margin101.6%+60.1pp

FCF margin-75%-30.5pp

Return on equity100.7%+60.3pp

Debt / equity0×-1.5×

Current ratio4.9×+1.9×

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept zvra:FairValueAdjustmentRelatedToDerivativeInstrument.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Zevra Therapeutics, Inc.'s fair value adjustment related to derivative instrument?: Zevra Therapeutics, Inc. (ZVRA) reported fair value adjustment related to derivative instrument of -$7.22M in Q1 2026.